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The optimal management strategy for patients with stable angina and documented coronary artery disease (CAD) 
remains controversial. The COURAGE (Clinical Outcomes 
Utilizing Revascularization and Aggressive Drug Evaluation) 
trial randomized patients to percutaneous coronary intervention 
(PCI) or best medical therapy alone and found that PCI reduced 
anginal symptoms and improved quality of life at 3 years but 
did not reduce the rates of death or myocardial infarction.1,2 
The cost-effectiveness of PCI in the COURAGE study was not 
favorable, however, with an incremental cost-effectiveness ratio 
(ICER) of ≥$168 000 per quality-adjusted life-year (QALY).3
Clinical Perspective on p 1340
Fractional flow reserve (FFR) measured with a coronary 
pressure wire during cardiac catheterization can identify 
functionally important coronary narrowings more accurately 
than visual assessment of the coronary angiogram.4 Use of 
FFR to guide PCI and treat only flow-limiting lesions was 
shown in the randomized FAME (Fractional Flow Reserve 
Versus Angiography for Multivessel Evaluation) trial to 
improve clinical outcomes and to have lower costs than 
angiography-guided PCI among patients with multivessel 
CAD.5,6 Subsequently, the FAME 2 trial randomized patients 
with stable angina, angiographically documented CAD, 
and ≥1 lesion with reduced FFR to either PCI or best medi-
cal therapy.7 The FAME 2 study was stopped early based on 
Background—The Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 2 trial demonstrated a 
significant reduction in subsequent coronary revascularization among patients with stable angina and at least 1 coronary 
lesion with a fractional flow reserve ≤0.80 who were randomized to percutaneous coronary intervention (PCI) compared 
with best medical therapy. The economic and quality-of-life implications of PCI in the setting of an abnormal fractional 
flow reserve are unknown.
Methods and Results—We calculated the cost of the index hospitalization based on initial resource use and follow-up 
costs based on Medicare reimbursements. We assessed patient utility using the EQ-5D health survey with US weights 
at baseline and 1 month and projected quality-adjusted life-years assuming a linear decline over 3 years in the 1-month 
utility improvements. We calculated the incremental cost-effectiveness ratio based on cumulative costs over 12 months. 
Initial costs were significantly higher for PCI in the setting of an abnormal fractional flow reserve than with medical 
therapy ($9927 versus $3900, P<0.001), but the $6027 difference narrowed over 1-year follow-up to $2883 (P<0.001), 
mostly because of the cost of subsequent revascularization procedures. Patient utility was improved more at 1 month with 
PCI than with medical therapy (0.054 versus 0.001 units, P<0.001). The incremental cost-effectiveness ratio of PCI was 
$36 000 per quality-adjusted life-year, which was robust in bootstrap replications and in sensitivity analyses.
Conclusions—PCI of coronary lesions with reduced fractional flow reserve improves outcomes and appears economically 
attractive compared with best medical therapy among patients with stable angina.
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the recommendation of the Data Safety Monitoring Board 
because of a significant reduction in the rate of hospitalization 
for urgent revascularization among patients assigned to PCI 
in the setting of an abnormal FFR, although the rates of death 
and myocardial infarction were similar between the 2 groups. 
In the present study, we sought to evaluate the economic and 
quality-of-life outcomes in the FAME 2 trial.
Methods
Study Design
The design and major clinical outcomes of the FAME 2 trial have 
been published previously.7 Briefly, FAME 2 was a prospective, 
international, randomized, controlled trial that enrolled patients 
with stable angina and CAD (1-, 2-, or 3-vessel disease) amenable 
to PCI with a second-generation drug-eluting stent. Before ran-
domization, FFR was measured across all lesions that appeared 
significant on visual assessment. Patients with an FFR >0.80 
across all lesions were followed up in a registry and not random-
ized. Patients with an FFR ≤0.80 across 1 or more lesions were 
randomly assigned to either PCI or to best medical therapy. The 
FAME 2 study population was therefore limited to patients with 
documented, significant myocardial ischemia caused by a coronary 
lesion amenable to PCI. The primary end point was the composite 
of death, myocardial infarction, or subsequent hospitalization with 
urgent coronary revascularization.
Costs
We calculated medical costs based on resource use and clinical events 
during the index procedure, hospitalization, and subsequent follow-
up. We counted the number of guiding catheters, coronary guidewires, 
balloon catheters, stents, medications, adverse events, and hospital 
days for each patient, as well as time in the cardiac catheterization 
laboratory, and applied cost weights in US dollars to calculate costs 
of the index procedure. We assigned costs to postdischarge events 
based on Medicare’s reimbursement rate per diagnosis-related group 
(DRG) for hospitalizations, inpatient procedures, outpatient tests, 
and physician fees and Internet pharmacy costs for cardiac medica-
tions.8 We calculated cumulative costs monthly for 12 months using 
an actuarial approach8 and adjusted all costs to 2012 US dollars using 
the Consumer Price Index (http://www.bls.gov). We did not discount 
costs because of the limited follow-up period.
Health Outcomes
Angina and employment status were assessed at baseline and at 1, 6, 
and 12 months. Patient utility was assessed with the EQ-5D health 
survey with US weights at baseline, 1 month, and 12 months.9
Framework of the Economic Evaluation
Analyses were performed from a societal perspective. We assessed 
the ICER as the difference in the cumulative costs of PCI in the set-
ting of an abnormal FFR and medical therapy, divided by the dif-
ference in cumulative QALYs of PCI in the setting of an abnormal 
FFR and medical therapy. Only 11% of patients provided 12-month 
EQ-5D scores because the trial was stopped early, so we used the 
baseline and 1-month EQ-5D data to calculate QALYs in the 2 treat-
ment groups. On the basis of previous data on the time course of 
angina relief and quality-of-life changes after coronary revascular-
ization,2,8 we assumed that the difference in the improvement from 
baseline in EQ-5D scores between the randomized groups would 
decline linearly to zero (ie, to no difference) over 3 years of follow-
up. We tested alternative QALY measures, including assumptions 
that the initial difference in utility would decline linearly to zero 
over 2 years or over 4 years. We also used an independent approach 
in which the change in utility from baseline to 1 month was assumed 
to last through the 12 months of in-trial follow-up in all patients, 
but follow-up was truncated at 12 months. In this approach, we also 
assumed patient utility would improve among patients assigned to 
the medical therapy arm at the time they underwent PCI and that the 
improvement would last for the remainder of the 12-month follow-
up period.
In all analyses, we made the conservative assumption that the dif-
ference in cumulative costs at 12 months between the PCI in the set-
ting of an abnormal FFR arm and the medical therapy arm would not 
change further over subsequent follow-up. We performed sensitivity 
analyses to assess the impact of different costs of coronary stents and 
by setting to zero the cost of the coronary pressure wire, the cath-
eterization procedure, and the baseline hospital stay in the medical 
therapy arm.
Statistical Analysis
We report categorical data as frequencies and continuous data as 
mean±SD. We compared categorical data using the χ2 test and 
continuous data (costs and QALYs) using the t test. Comparisons 
between baseline and 1-month utilities were made by the paired t test, 
whereas comparisons of differences between groups were made by 
the 2- sample t test. We computed confidence intervals for differences 
in costs and QALYs and in the ICER using the bootstrap technique 
with the percentile method with 10 000 replications.
Results
The FAME 2 trial was stopped after 888 patients had been 
randomized, with a median follow-up of 208 days (first, 
third quartiles, 103–312 days) in the PCI arm and 209 days 
(first, third quartiles, 106–314 days) in the medical therapy 
arm.7 The baseline characteristics were similar between the 
2 groups (Table 1). The primary composite end point of death, 
myocardial infarction, and urgent revascularization occurred 
in 4.3% of the 447 patients randomized to PCI in the setting 
of an abnormal FFR and in 12.7% of the 441 patients random-
ized to medical therapy (P<0.001). There was no difference in 
the rate of death (0.2% versus 0.7%, P=0.31) or myocardial 
infarction (3.4% versus 3.2%, P=0.89), but there was a highly 
significant difference in the rate of urgent revascularization 
(1.6% versus 11.1%, P<0.001).
The initial procedure and hospitalization cost was signifi-
cantly greater among patients randomized to PCI than among 
Table 1. Baseline Characteristics
Characteristic
FFR-Guided PCI
(n=447)
Medical Therapy
(n=441)
Age, y 63.5±9.4 63.9±9.6
Male 80 77
Diabetes mellitus 28 27
Hypertension 78 78
Dyslipidemia 74 79
Tobacco use 20 20
Previous MI 36 37
Previous PCI 37 38
CCS class II or greater 
angina
70 67
Angiographically 
significant lesions 
(number per patient)
1.9±1.1 1.7±0.9
CCS indicates Canadian Cardiovascular Society; FFR, fractional flow reserve; 
MI, myocardial infarction; and PCI, percutaneous coronary intervention.
Values are percentages or mean±SD.
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patients randomized to medical therapy ($9927 versus $3900, 
P<0.001; Figure 1). The $6027 initial cost difference was 
driven primarily by the cost of the PCI procedure (Table 2). 
Over the subsequent year, follow-up costs were higher in the 
medical therapy arm, such that the cumulative costs at 12 
months were $12 646 in the PCI arm compared with $9763 
in the medical therapy arm (P<0.001). The higher follow-
up costs in the medical therapy arm were driven primarily 
by the higher rate of revascularization (Table 3). The higher 
cost of antiplatelet therapy in the PCI arm was balanced by 
the higher cost of antianginal agents in the medical therapy 
arm (Table 3).
At 30 days, significantly fewer patients in the PCI arm had 
Canadian Cardiovascular Society class 2 or greater angina 
(11.1% versus 28.9%, P<0.0001) than those receiving medi-
cal therapy alone. The change in patient utility from base-
line to 30 days was significantly greater in the PCI arm than 
in the medical therapy arm (0.054 versus 0.001, P<0.0001; 
Table 4). In the 11% of patients who achieved 1-year follow-
up, there was a nonsignificant 0.02 decline in utility from 1 
to 12 months in both groups. There was little effect of either 
therapy on employment, with a −3.8% net change in work sta-
tus among patients assigned to PCI (P=0.38), and a −4.4% 
net change in work status among patients assigned to medical 
therapy (P=0.18) between baseline and 6 months.
Assuming that the effect of PCI on utility would decline 
linearly over 3 years and that the cost difference present at 
1 year would not change, the ICER for PCI compared with 
medical therapy was $36 000/QALY. The ICER was below 
a willingness-to-pay threshold of $50 000/QALY in most 
(80%) of the 10 000 bootstrap replications and was below the 
$100 000/QALY threshold in almost all (99.5%) replications 
(Figures 2 and 3).
Figure 1. Cumulative medical costs (vertical axis) of a strategy 
of percutaneous coronary intervention (PCI) in the setting of an 
abnormal fractional flow reserve (FFR; solid line) and a medical 
therapy strategy (dashed line) over 12 months of follow-up 
(horizontal axis).
Table 2. Resource Use at Initial Procedure
Resource (Cost)
Mean Cost per Patient, $
FFR-Guided PCI Medical Therapy
Cathaterization laboratory 1209 709
Guide catheter ($52) 75 72
Guidewire ($51) 49 15
Pressure wire ($650) 650 603
Balloon catheter ($166) 293 3
Drug-eluting stent ($1656) 2612 15
Bare-metal stent ($809) 38 2
Adenosine ($150/vial) 87 67
GPI ($500/vial) 70 0
Hospital day ($2000) 3067 2018
Professional fee ($796) 796 0
Staged PCI 567 29
Other 414 367
Total baseline costs 9927 3900
FFR indicates fractional flow reserve; GPI, glycoprotein inhibitor; and PCI, 
percutaneous coronary intervention.
Table 3. Resource Use and Cumulative Costs During 
12-Month Follow-Up
Resource
FFR-Guided PCI  
(n=447)
Medical Therapy  
(n=441)
No. per group
  Hospitalizations 88 144
  Hospital days 446 861
  Outpatient visits 249 251
  Exercise tests 56 39
  Coronary angiograms 27 39
Cost per patient, $
  Nonurgent PCI ($11 166) 269 1751
  Urgent PCI ($11 166) 193 1248
  CABG ($27 207) 70 1099
  Medications 942 874
  Antiplatelet therapy 229 111
  Antianginal therapy 167 218
  Laboratory tests 283 371
  Adverse events 962 520
Total follow-up costs, $ 2719 5863
Total 12-month costs, $ 12 646 9763
The top portion of Table 3 lists absolute counts of events during the observed 
follow-up, which gives a picture of the differences in medical utilization between the 
2 groups. The bottom portion of the table lists the cumulative cost over 12 months 
in the 2 groups, which uses an actuarial technique to account for patients with less 
than the full 12 months of follow-up. CABG indicates coronary artery bypass graft; 
FFR, fractional flow reserve; and PCI, percutaneous coronary intervention.
Table 4. EQ-5D Health Utilities by Treatment Groups
Treatment Arm Baseline 1 mo Difference P Value
FFR-guided PCI 0.817±0.160 0.871±0.154 0.054 <0.0001
Medical therapy 0.845±0.144 0.846±0.148 0.001 0.86
FFR indicates fractional flow reserve; and PCI, percutaneous coronary 
intervention.
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The ICER for PCI was changed in several sensitivity analy-
ses but remained in the $100 000/QALY range or less. When 
we arbitrarily assumed the cost of a drug-eluting stent was 
$400 higher than our base case estimate of $1656 per stent, the 
ICER increased to $44 000/QALY, whereas if we assumed the 
stent cost was $400 lower than the base case, the ICER became 
$29 000/QALY. When we set the cost of the pressure wire to 
zero in the medical treatment arm, the ICER became $44 000/
QALY. If we assumed the utility benefit of PCI dissipated over 
2 years rather than the base case of 3 years, ICER became 
$54 000/QALY, whereas if we assumed the utility benefit 
would dissipate over 4 years, the ICER changed to $27 000/
QALY. If we set the cost of the nonurgent PCIs in follow-up to 
zero in the medical therapy arm, the ICER changed to $55 000/
QALY. If we limited the follow-up period to 12 months and 
assumed that medically treated patients after a subsequent 
PCI had an increase in utility of 0.053, the ICER for PCI 
became $60 000/QALY. Symptom status did have more of an 
effect on the ICER; when we analyzed the cost-effectiveness 
of patients with Canadian Cardiovascular Society class 0/1 
angina, it was $102 000/QALY compared with $26 000/QALY 
in those patients with Canadian Cardiovascular Society class 
2 to 4 angina. If Medicare costs were used for the index PCI 
and there was no change in the baseline costs in the medi-
cal therapy arm, the 1-year cost differential would increase 
by approximately $2000 and the ICER would increase to 
$63 000/QALY. Finally, if we excluded the baseline cost of 
the catheterization procedure and hospital stay in the medical 
therapy arm, the ICER for PCI became $63 000/QALY.
Discussion
FFR measured during coronary angiography accurately iden-
tifies flow-limiting coronary lesions. The FAME 2 trial dem-
onstrated that PCI of coronary lesions with an FFR ≤0.80 
improves clinical outcomes compared with best medical 
therapy. The present study shows that PCI in the setting of 
an abnormal FFR also reduces angina and improves patient 
utility significantly. Although by design the PCI strategy had 
higher initial costs than the medical therapy strategy, the dif-
ference in cost between these strategies was cut by more than 
half over 1 year of follow-up (Figure 1). PCI in the setting 
of an abnormal FFR appears to provide good value for the 
added cost, with an ICER well below the standard willing-
ness to pay threshold of $50 000 per QALY, a finding that was 
robust in bootstrap replications (Figure 2) and several sensitiv-
ity analyses.
The COURAGE trial compared PCI with medical ther-
apy in patients with stable CAD but found PCI to be eco-
nomically unattractive despite significant improvements 
in angina and quality of life, with ICERs ranging between 
$168 000 and $300 000 per QALY.3 By contrast, FAME 2 
found an ICER of $36 000 per QALY for PCI in the set-
ting of an abnormal FFR. The most likely explanation for 
these different results is that PCI in COURAGE was guided 
by the visual appearance of the lesion on coronary angiog-
raphy, whereas PCI in FAME 2 was guided by identifica-
tion of functionally significant lesions based on a measured 
FFR ≤0.80. The measurement of FFR in FAME 2 excluded 
26% of otherwise eligible patients from PCI because they 
did not have a functionally significant lesion despite having 
Figure 3. Cost-effectiveness acceptability curve of the 
incremental cost-effectiveness of the fractional flow reserve–
guided strategy compared with best medical therapy, based 
on 10 000 bootstrap replications. The cumulative percentage 
of replications (vertical axis) below various willingness-to-pay 
thresholds (horizontal axis) in dollars per quality-adjusted 
life-year (QALY) is shown. The points on the curve indicate 
the cumulative proportion of replications below thresholds of 
$25 000/QALY (18%), $50 000/QALY (80%), $75 000/QALY 
(97%), $100 000/QALY (99.5%), $125 000/QALY (99.9%), and 
$150 000/QALY (99.97%).
Figure 2. Bootstrap replications of the incremental cost-
effectiveness of the strategy of percutaneous coronary 
intervention in the setting of an abnormal fractional flow reserve 
compared with best medical therapy. Each of the 10 000 points 
represents the results of 1 bootstrap replication. The difference 
in cumulative costs is displayed in the vertical axis, and the 
difference in quality-adjusted life-years (QALYs) is displayed on 
the horizontal axis. Willingness-to-pay thresholds of $50 000 per 
QALY added (solid line), $100 000 per QALY added (dashed line), 
and $150 000 per QALY added (dotted line) are indicated in the 
plane. The fractions of replications in each sector of the plane are 
indicated (eg, 0.0023 of the replications had a cost difference <0 
and QALY difference >0).
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angiographically significant CAD.7 Furthermore, 19% of 
patients in FAME 2 who had a lesion with an FFR ≤0.80 
had another lesion with an FFR >0.80. All of these patients 
and lesions presumably would have been treated with PCI 
in COURAGE, with little benefit and perhaps harm because 
of the absence of significant ischemia.5 Thus, the targeting 
of PCI in FAME 2 to the patients and lesions most likely to 
benefit from it may have reduced unnecessary procedures 
and increased the efficiency of PCI and thereby led to a 
more favorable ICER than with medical therapy.
There were other differences between the COURAGE and 
the FAME 2 trials that may have affected the economic eval-
uation. In COURAGE, a significant proportion of patients 
had few, if any, angina symptoms, which may explain in 
part the smaller utility change after PCI documented in the 
COURAGE trial. The higher initial difference in cost of 
$11 410 between the PCI arm and the medical therapy arm 
in COURAGE compared with FAME 2 ($6027) was pri-
marily attributable to the much lower initial cost assigned 
to the medical therapy arm in COURAGE (only $752 per 
patient) compared with FAME 2 ($3900 per patient). The 
cost of the PCI procedures in FAME 2 was also lower than 
in COURAGE, perhaps because fewer stents were used with 
PCI in the setting of an abnormal FFR. The more striking 
difference between studies is that the initial cost difference 
between PCI and medical therapy in COURAGE was essen-
tially unchanged over 3 years of follow-up, despite a 40% 
reduction in the rate of subsequent coronary revasculariza-
tion procedures among patients assigned to the PCI strat-
egy. By contrast, in FAME 2, the initial difference in cost 
between PCI in the setting of an abnormal FFR and medical 
therapy narrowed over follow-up (Figure 1) because of a sig-
nificantly higher rate of hospitalizations for acute coronary 
syndromes and for revascularization. The follow-up costs in 
the PCI arm of FAME 2 may have been further lowered com-
pared with the PCI arm in COURAGE by the use of second-
generation drug-eluting stents, which have had lower rates 
of restenosis than the bare-metal stents used in COURAGE.
The FAME 1 trial compared FFR-guided PCI with angiog-
raphy-guided PCI, like that used in COURAGE, in patients 
with stable and unstable multivessel CAD.5
 The economic 
evaluation of FAME 1 found that FFR-guided PCI led to 
improved clinical outcomes at lower costs (by $2000 per 
patient at 1 year) than angiography-guided PCI.6 In the FAME 
2 trial, application of FFR guidance may have allowed for 
more judicious stenting in those patients with significant 
myocardial ischemia. By stenting only those lesions respon-
sible for ischemia and medically treating the lesions that were 
not functionally significant, the benefit of PCI may have been 
maximized and the risks minimized.
The main limitation of the present study is that follow-up 
in FAME 2 was shorter than originally planned because of 
the premature discontinuation of the trial based on the rec-
ommendation of the Data and Safety Monitoring Board. As a 
result of the limited time horizon, we had to make a number 
of assumptions regarding the follow-up costs and durability 
of the benefit from PCI. The key assumption was that the ini-
tial benefit of PCI seen at 1 month would gradually diminish 
to zero over 3 years of follow-up. This assumption is based 
on the results of COURAGE and other studies in which the 
improvements in angina and quality of life from coronary 
revascularization declined over 3 years or more.1,10 The 
present results were similar, however, in various sensitivity 
analyses that varied the period of benefit between 1 and 4 
years. Consequently, we believe that the projections of the 
durability of the benefit from PCI are reasonable. The early 
termination of the study may have also led to an overesti-
mation of benefit by PCI. The other major limitation is that 
all patients in FAME 2 had FFR performed, so we cannot 
directly address the cost-effectiveness per se of using FFR. 
The initial FAME trial previously has shown the FFR-guided 
PCI strategy to have superior clinical outcomes and lower 
costs than standard, visually guided PCI.5
Conclusions
In patients with symptomatic stable coronary artery disease, 
PCI in the setting of an abnormal FFR improves angina and 
quality of life and appears to be economically attractive com-
pared with best medical therapy if one assumes that the benefit 
of PCI lasts longer than 1 year.
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CLINICAL PERSPECTIvE
The Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 2 Trial randomized patients with 
stable coronary artery disease and at least 1 stenosis with an abnormal fractional flow reserve to either percutaneous coronary 
intervention (PCI) or medical therapy alone. Patients randomized to PCI had a significantly lower rate of hospitalization 
requiring urgent revascularization, with no difference in death or myocardial infarction. In this substudy of the FAME 2 
Trial, we evaluate the economic and quality-of-life implications of performing PCI in patients with stable coronary artery 
disease and an abnormal fractional flow reserve. We found significantly higher costs in the PCI arm at baseline, primarily 
attributable to drug-eluting stents. During follow-up, the cost difference between the 2 groups narrowed significantly, pri-
marily because of the increased costs in the medical therapy arm from revascularization. The PCI patients had an immediate 
and significant improvement in quality of life. Assuming the initial difference in utility between the 2 groups gradually nar-
rowed over 3 years, and assuming the difference in costs at 1 year did not change, the incremental cost-effectiveness ratio of 
PCI was $36 000 per quality-adjusted life-year. These findings were robust in bootstrap replications and sensitivity analyses. 
PCI of coronary lesions with reduced fractional flow reserve improves outcomes and appears economically attractive com-
pared with best medical therapy among patients with stable angina.
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